Frederick J. Fritz net worth and biography

Frederick Fritz Biography and Net Worth

Director of Imunon

Frederick J. Fritz was appointed to the Board of Directors in July 2011. He is the CEO and Founder of NeuroDx, a development-stage diagnostic device company focused on the neurosurgery market. Mr. Fritz joined NeuroDx from Valeo Medical, a biotech company he founded in 2003, to develop the world’s first noninvasive diagnostic test for endometriosis. Prior to that, Mr. Fritz was President and CEO of Songbird Hearing, a medical device company spin-off of Sarnoff Corp. Mr. Fritz began his career in marketing management and new product development. He joined Schering Plough’s Wesley Jessen in 1985 as Vice President, Marketing and Sales. He was promoted to general manager of Schering’s OTC pharmaceutical business in 1988 and of the podiatric products business in 1990. Additionally, Mr. Fritz was President of Coleman North America from 1995-1997. He holds an Engineering degree from the University of Illinois, from which he was graduated Summa Cum Laude, and an MBA from Harvard Business School.

What is Frederick J. Fritz's net worth?: The estimated net worth of Frederick J. Fritz is at least $0.00 as of April 8th, 2022. Mr. Fritz owns 11,766 shares of Imunon stock worth more than $0 as of April 18th. This net worth evaluation does not reflect any other assets that Mr. Fritz may own. Learn More about Frederick J. Fritz's net worth.
How do I contact Frederick J. Fritz?: The corporate mailing address for Mr. Fritz and other Imunon executives is 997 LENOX DRIVE SUITE 100, LAWRENCEVILLE NJ, 08648. Imunon can also be reached via phone at (609) 896-9100 and via email at [email protected]. Learn More on Frederick J. Fritz's contact information.
Has Frederick J. Fritz been buying or selling shares of Imunon?: Frederick J. Fritz has not been actively trading shares of Imunon in the last ninety days. Most recently, on Friday, April 8th, Frederick J. Fritz bought 5,000 shares of Imunon stock. The stock was acquired at an average cost of $4.05 per share, with a total value of $20,250.00. Following the completion of the transaction, the director now directly owns 11,766 shares of the company's stock, valued at $47,652.30. Learn More on Frederick J. Fritz's trading history.
Who are Imunon's active insiders?: Imunon's insider roster includes Donald Braun (Director), and Frederick Fritz (Director). Learn More on Imunon's active insiders.

Frederick J. Fritz Insider Trading History at Imunon

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/8/2022	Buy	5,000	$4.05	$20,250.00	11,766
3/2/2022	Buy	2,000	$4.69	$9,380.00
10/7/2021	Buy	20,000	$0.88	$17,600.00
11/6/2019	Buy	10,000	$1.39	$13,900.00	51,491
8/2/2019	Buy	10,000	$1.73	$17,300.00	41,491
7/24/2019	Buy	10,000	$1.73	$17,300.00	31,491
3/6/2019	Buy	3,400	$2.13	$7,242.00	21,491
9/20/2018	Buy	5,000	$2.70	$13,500.00	18,091
8/15/2018	Buy	2,750	$2.37	$6,517.50	15,591
2/20/2018	Buy	6,000	$2.17	$13,020.00	12,841
7/7/2017	Buy	13,000	$1.89	$24,570.00	9,841
12/18/2014	Buy	4,000	$2.34	$9,360.00
8/14/2014	Buy	4,000	$3.20	$12,800.00

Frederick J. Fritz Buying and Selling Activity at Imunon

Imunon Company Overview

Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.

Today's Range

Now: N/A

50 Day Range

MA: $2.22

$1.95

$2.63

2 Week Range

Now: N/A

Volume

711 shs

Average Volume

150,471 shs

Market Capitalization

$13.91 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.27

Biden’s $374B Giveaway Into This Sector

From DTI | Ad

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story